Industry News: Definiens takes CAD into the lymph nodes

Article

Definiens introduced its latest CAD system as a way to judge the effects of therapy on some cancer patients.

Definiens introduced its latest CAD system as a way to judge the effects of therapy on some cancer patients. Dubbed LymphExpert, the CAD technology helps detect the metastatic spread of cancer by better identifying, analyzing, and measuring volumetric changes in the size of lymph nodes. The CAD software promises to save time and make study results more consistent by automating segmentation and analysis of the nodes.
LymphExpert is brought in after a radiologist has manually detected lymph nodes in a CT image, automatically segmenting and quantifying the nodes according to established guidelines, then reconstructing a volumetric image. Definiens contends that a precise 3D picture of a lymph node's growth or shrinkage over time indicates cancer progression or remission. The Munich-based company, founded in 1986 by Nobel Laureate Gerd Binnig, develops "cognitive emulation" software that automates and quantifies challenging image analysis challenges.
 

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.